Clinical trial
A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma
NCT03593109 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Xi'an Jiaotong University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma
- Lead sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- May 30, 2019
- Completion date
- May 1, 2021
- Enrollment
- 1 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.